ReviewCancers2022
Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Combined RAS and SMAD4 Mutations and Microsatellite Instability Predict Outcomes in Colorectal Lung Metastases Treated with Image-Guided Thermal Ablation.Annals of surgical oncology · 2026Article
- Worse Survival in Co-Altered RAS-TP53 Patients With Resected Colorectal Liver Metastases.Annals of surgical oncology · 2026Article
- Comment on "Combating colorectal lung metastases via systemic therapy and thermal ablation: RAS mutation impact".International journal of surgery (London, England) · 2026Article
- Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy.Biomedicines · 2025Review
- Prognostic Factors in Colorectal Liver Metastases: An Exhaustive Review of the Literature and Future Prospectives.Cancers · 2025Review
- The Impact of KRAS Status on Long-Term Outcomes After Thermal Ablation and Hepatic Resection for Liver-Only Colorectal Metastases: A New Clue for Tailoring Surgical Strategy on Tumor Biology?World journal of surgery · 2025Article
- Thermal ablation in the curative treatment of colorectal liver metastasis: new standard of care?-lessons learned from the COLLISION trial.Hepatobiliary surgery and nutrition · 2025Article
- Impact of Caudate Lobe Resection on Overall Survival and Liver Disease-Free Survival in Colorectal Liver Metastases: A Pilot Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Review
- Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases.Hepatology international · 2024Article
- Long-term results of liver thermal ablation in patients with hepatocellular carcinoma and colorectal cancer liver metastasis regarding spatial features and tumor-specific variablesDiagnostic and interventional radiology (Ankara, Turkey) · 2024Article
- ATP6AP1 as a potential prognostic biomarker in CRC by comprehensive analysis and verification.Scientific reports · 2024Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related death. More than 50% of patients with CRC will develop liver metastases (CRLM) during their disease. In the era of precision surgery for CRLM, several advances have been made in the multimodal management of this disease. Surgical treatment, combined with a modern chemotherapy regimen and targeted therapies, is the only potential curative treatment. Unfortunately, 70% of patients treated for CRLM experience recurrence. RAS mutations are associated with worse overall and recurrence-free survival. Other mutations such as BRAF, associated RAS /TP53 and APC/PIK3CA mutations are important genetic markers to evaluate tumor biology. Somatic mutations are of paramount interest for tailoring preoperative treatment, defining a surgical resection strategy and the indication for ablation techniques. Herein, the most relevant studies dealing with RAS mutations and the management of CRLM were reviewed. Controversies about the implication of this mutation in surgical and ablative treatments were also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.